Skip to main content
. Author manuscript; available in PMC: 2020 Oct 9.
Published in final edited form as: Circ Arrhythm Electrophysiol. 2019 Oct 9;12(10):e005557. doi: 10.1161/CIRCEP.117.005557

Figure 8: Effects of ranolazine and dofetilide in persistent AF.

Figure 8:

(A) In hearts from 5 sheep with tachypacing-induced persistent AF, after at least 30 minutes of baseline AF, 10 μM ranolazine was added to the perfusate for 15 minutes, followed by an increase in ranolazine concentration to 20 μM for 15 minutes, and lastly the addition of dofetilide (1 μM). The addition of dofetilide to ranolazine (20 μM) did not terminate persistent AF in any of the hearts, despite decreasing average DF on the LA epicardium (* p<0.05 versus end of baseline). (B) The higher concentration of ranolazine plus dofetilide did not significantly change average SP frequency on the LA epicardium (p=n.s. versus end of baseline).